Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01995825 · ClinicalTrials.gov registry record · Phase 4
Lamotrigine Bioequivalence
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT01995825 is a Phase 4 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 35 participants.
The verdict
NCT01995825, a Phase 4 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
In this study, brand name lamotrigine (LAMICTAL) and generic lamotrigine will be compared in patients with epilepsy. Both the brand name and generic lamotrigine are approved by the Food and Drug Administration (FDA) and are commonly used to treat epilepsy. Some physicians and patients with epilepsy have believed that brand and generic lamotrigine have had clinically significant differences in efficacy and tolerability. The brand name and generic tablets have been shown to be the same when blood levels were measured in healthy volunteers without epilepsy, but these drugs have not yet been compared in patients with epilepsy. This study will do this comparison, by switching patients between brand and generic in a very structured manner, and seeing if the drugs are the same, primarily in terms of blood levels. Other comparisons will also be made secondarily, looking for any differences in adverse effects and seizure control.
Interventions
- DRUG Brand lamotrigine
- DRUG Generic lamotrigine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01995825
The ClinicalTrials.gov registry entry for NCT01995825 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brand lamotrigine is the first listed.
NCT01995825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01995825 about?
NCT01995825 is a clinical study titled "Lamotrigine Bioequivalence". In this study, brand name lamotrigine (LAMICTAL) and generic lamotrigine will be compared in patients with epilepsy. Both the brand name and generic lamotrigine are approved by the Food and Drug Administration (FDA) and are commonly used to treat epilepsy. Some physicians and patients with epilepsy ...
What is the current status of trial NCT01995825?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2012-05. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01995825?
The interventions under investigation include: Brand lamotrigine (DRUG), Generic lamotrigine (DRUG).
Who is sponsoring clinical trial NCT01995825?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.